Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4352 - Steroid switch: Reversal of resistance to abirateron acetate (AA) and prednisolone (P) combination in metastatic castration-resistant prostate cancer (mCRPC) patients

Date

10 Sep 2017

Session

Poster display session

Presenters

Fruzsina Gyergyay

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

F. Gyergyay1, B. Budai2, K. Biro1, Z. Küronya1, K. Nagyivanyi1, L. Geczi1

Author affiliations

  • 1 Chemotherapy, National Institute of Oncology, 1122 - Budapest/HU
  • 2 Department Of Molecular Genetics, National Institute of Oncology, 1122 - Budapest/HU
More

Resources

Abstract 4352

Background

AA+P has shown to improve overall survival (OS) in large, randomized trial in the treatment of mCRPC both in pre and post-docetaxel setting. AA is a steroidal CYP17A1 inhibitor, which suppresses androgen synthesis. Because of secondary mineralocorticoid excess it is licensed in combination with P.

Methods

Based on previous data reporting responses following steroid switch upon progression during AA+P a prospective study in mCRPC pts was started. (Lorente at al BJC (2014) 111, 2248–2253).

Results

23 mCRPC pts were treated with AA (1000 mg q.d.) and P (5 mg b.i.d). Pts characteristics were as follows: median age 73 (95% CI 69-77) years, median Gleason score 8 (7-9), time-span since diagnosis was median 5.6 (3.6-7.8) yrs and all pts. had previous docetaxel treatment and received concomitant androgen deprivation treatment. Pts were on AA+P therapy for median 11.4 (6.4-19.8) mos. In case of PSA progression steroid switch has been applied to dexamethasone (D) (0.5 mg q.d). The PSA progression-free survival on AA+D combination was 5 (3.7-5) mos. 13 (57%) pts are still on AA+D treatment. The OS for AA was 53 (39-53) mos.Table:

799P

SchedulePSA progression-free survival (mos)PSA (ng/ml) at startPSA (ng/ml) nadir
AA+PMedian11.49932.5
95% CI6.4 -19.830-12913-98
AA+DMedian55241.5
95% CI3.7 - 527-13320-100

During AA+P therapy >25% decrease in PSA occurred in 65% of pts and further decrease (>25%, compared to the nadir during AA+P treatment) has been seen in 26% pts during AA+D treatment.

Conclusions

D can induce further response during AA therapy by reversing glucocorticoid receptor activation or by superior activity of D administered even as a single agent. Our data supports that steroid switch may induce further PSA regression.

Clinical trial identification

Legal entity responsible for the study

Fruzsina Gyergyay

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.